Why Is Cell & Gene Therapy-Focused Senti Biosciences Stock Trading Higher Today?

Senti Biosciences Inc (NASDAQ: SNTI) announced a new strategic collaboration with Celest Therapeutics (Shanghai) Co Ltd, a China-based biotechnology company, for the clinical development of SENTI-301A to treat solid tumors in China.

SENTI-301A is a multi-armed, off-the-shelf, healthy donor-derived CAR-NK cell therapy designed for GPC3-expressing tumors. 

Through this collaboration, Celest will lead clinical development, operations, and manufacturing to advance SENTI-301A with technical support from Senti ...

Full story available on Benzinga.com

Disclaimer: The views, recommendations, and opinions expressed in this content belong solely to the third-party experts. This site was not involved in the writing and production of this article.

Disclaimer Press Release Banner